DNTH
Dianthus Therapeutics, Inc. /DE/Company Information
- Company Name
- Dianthus Therapeutics, Inc. /DE/
- CIK
- CIK0001690585
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- DNTH: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DNTH
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-09-29
- Last sale
- 2026-09-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 807,219
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 59,176,285
- Shares outstanding
- 56,029,124
- Ownership
- 105.62%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -4.13%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 111 | 628 | 51 | 56 | 13 | 10 | 23 | 34 | 314 | 330 | 132 | 157 | ||||||
| Short Term Investments | 776 | 484 | 353 | 347 | 244 | 253 | 252 | 247 | 47 | 47 | 41 | 33 | ||||||
| Other Receivables Net Current | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 0 | 1 | 0 | 5 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | ||||||
| Unbilled Receivables Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Prepaid Expense And Other Assets Current | 11 | 7 | 5 | 6 | 6 | 7 | 5 | 4 | 3 | 3 | 3 | 1 | ||||||
| Assets Current | 898 | 1,120 | 409 | 414 | 264 | 271 | 281 | 287 | 366 | 381 | 177 | 191 | ||||||
| Long Term Investments | 304 | 114 | 110 | 153 | 52 | 68 | 82 | 61 | - | - | 0 | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | ||||||
| Assets | 1,213 | 1,247 | 531 | 577 | 326 | 349 | 374 | 354 | 369 | 382 | 179 | 192 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 5 | 10 | 7 | 5 | 8 | 5 | 8 | 4 | 3 | 3 | 1 | ||||||
| Accrued Liabilities Current | 26 | 31 | 19 | 16 | 14 | 8 | 13 | 8 | 6 | 6 | 7 | 11 | ||||||
| Deferred Revenue Current | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 34 | 38 | 31 | 24 | 20 | 17 | 18 | 16 | 10 | 9 | 10 | 13 | ||||||
| Deferred Revenue Noncurrent | 6 | 6 | 6 | 6 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 1 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 41 | 46 | 38 | 31 | 23 | 20 | 22 | 16 | 11 | 10 | 11 | 14 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,602 | 1,579 | 830 | 819 | 538 | 532 | 527 | 483 | 479 | 476 | 258 | 257 | ||||||
| Retained Earnings Accumulated Deficit | -428 | -378 | -337 | -272 | -236 | -204 | -174 | -146 | -121 | -103 | -89 | -79 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Stockholders Equity | 1,172 | 1,201 | 493 | 546 | 303 | 329 | 352 | 338 | 358 | 373 | 169 | 178 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Liabilities And Stockholders Equity | 1,213 | 1,247 | 531 | 577 | 326 | 349 | 374 | 354 | 369 | 382 | 179 | 192 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 55 | 55 | 43 | 43 | 32 | 32 | 31 | 29 | 29 | 29 | 15 | 11 | ||||||
| Shares Outstanding | 55 | 55 | 43 | 43 | 32 | 32 | 31 | 29 | 29 | 29 | 15 | 15 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDianthus Therapeutics, Inc. /DE/ (DNTH) — SEC Financial Statements & Analysis
Dianthus Therapeutics, Inc. /DE/ (DNTH) is a pharmaceutical preparations company, incorporated in DE. Dianthus Therapeutics, Inc. /DE/ trades on Nasdaq as: DNTH. Dianthus Therapeutics, Inc. /DE/ (DNTH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Dianthus Therapeutics, Inc. /DE/ carries a market cap of $5.46B, a P/E ratio of -28.41x, a P/B ratio of 4.66x, a P/S ratio of 2868.55x, an enterprise value of $5.35B, and an EV/EBITDA multiple of -24.58x. On profitability, it posts an operating margin of -11441.39%, a net margin of -10096.95%, a Return on Equity (ROE) of -26.07%, a Return on Assets (ROA) of -24.98%, and a Return on Invested Capital (ROIC) of -32.24%. Per share, it reports EPS of $-3.43, diluted EPS of $-3.43, free cash flow per share of $-2.78, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -60.77% year-over-year, net income growth of 67.53% year-over-year, and EPS growth of 7.11% year-over-year. On the balance sheet, it maintains a current ratio of 26.10x, a quick ratio of 25.79x, working capital of $863.15M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.03, free cash flow of $-155.71M (TTM), and net debt of $-110.55M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.46B
- P/E TTM
- -28.41x
- EPS TTM
- $-3.43
- P/B TTM
- 4.66x
- ROE TTM
- -26.07%
- ROA TTM
- -24.98%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-155.71M
- Net Revenue TTM Growth 1Y
- -60.77%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Dianthus Therapeutics, Inc. /DE/ in?
Dianthus Therapeutics, Inc. /DE/ (DNTH) operates in the Pharmaceutical Preparations industry.
What exchange does DNTH trade on?
Dianthus Therapeutics, Inc. /DE/ (DNTH) trades on the Nasdaq.
Where is Dianthus Therapeutics, Inc. /DE/ incorporated?
Dianthus Therapeutics, Inc. /DE/ is incorporated in DE.
When was Dianthus Therapeutics, Inc. /DE/ (DNTH)'s most recent SEC filing?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is DNTH's market cap?
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a market capitalization of $5.46B as of 2026-06-30.
What is DNTH's EPS (earnings per share)?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s trailing twelve month EPS is $-3.43 as of 2026-06-30.
What is DNTH's ROE (return on equity)?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s trailing twelve month Return on Equity (ROE) is -26.07% as of 2026-06-30.
What is DNTH's ROA (return on assets)?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s trailing twelve month Return on Assets (ROA) is -24.98% as of 2026-06-30.
What is DNTH's ROIC (return on invested capital)?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s trailing twelve month Return on Invested Capital (ROIC) is -32.24% as of 2026-06-30.
What is DNTH's EV/EBITDA?
Dianthus Therapeutics, Inc. /DE/ (DNTH)'s trailing twelve month EV/EBITDA is -24.58x as of 2026-06-30.